In addition to T cell checkpoint inhibitors, a recent addition to the armamentarium is the macrophage checkpoint inhibitor magrolimab, which targets CD47, and has shown promising activity in combination with azacitidine in newly diagnosed AML patients who are unfit for intensive therapy with an objective response rate of 71% in TP53-mutated AML (103). This evidence concerns the gene TP53 and acute myeloid leukemia.